ITGB8 Knockout A-549 Polyclonal Cells are a genetically engineered A-549-derived cell product in which the ITGB8 gene has been disrupted using CRISPR/Cas9 technology, generating a polyclonal knockout cell population. This format provides a heterogeneous pool of edited cells, each carrying gene-targeting events that abolish functional integrin ??8 expression, without selection for a single clonal isolate. The polyclonal composition preserves biological diversity while ensuring robust loss-of-function across the population, making the product suitable for experiments that require a representative knockout background rather than a monoclonal derivative. By eliminating integrin ??8, the model enables direct interrogation of ITGB8-dependent pathways in a lung epithelial carcinoma context.
A-549 cells are an extensively characterized human lung adenocarcinoma line originally established from the tumor tissue of a 58-year-old Caucasian male. As adenocarcinomic alveolar basal epithelial cells, they retain key features of type II pneumocytes, including adherent epithelial morphology, expression of surfactant proteins, and functional signaling networks relevant to lung cancer biology. The A-549 background is a workhorse model for respiratory disease research, particularly for studying oncogenic transformation, drug response, and the tumor microenvironment. Derivation of the ITGB8 knockout in this well-defined cell line allows investigators to dissect integrin ??8 contributions within a clinically pertinent lung carcinoma setting.
The ITGB8 gene encodes integrin ??8, a subunit that exclusively pairs with integrin ??V to form the ??v??8 heterodimer. This receptor binds RGD-containing extracellular matrix proteins such as fibronectin (FN1) and vitronectin (VTN) and, critically, engages the latency-associated peptide (LAP) of transforming growth factor-?? (TGF-??) to mediate mechanical activation of the latent cytokine. Integrin ??v??8 thus serves as a major activator of TGF-?? in epithelial and immune cells, triggering downstream signaling through TGF-?? receptor?Cmediated phosphorylation of SMAD2 and SMAD3, which complex with SMAD4 to regulate gene expression. The ITGB8 signaling network is modulated by upstream drivers including TGFB1, EGF, FGF2, MAPK1, SMAD3, and SP1, and feeds into effectors such as FAK, SRC, and transcription factors SNAI1 and TWIST1. Direct interaction partners include talin and kindlin, which link the integrin to the actin cytoskeleton. Disruption of ITGB8 therefore intercepts ??v??8?CTGF-?? axis communication, abrogating signal propagation to SERPINE1, CTGF, and other profibrotic and promigratory targets.
In A-549 lung carcinoma cells, endogenous ITGB8 contributes to autocrine and paracrine TGF-?? activation, sustaining epithelial?Cmesenchymal transition (EMT)-like states, matrix remodeling, and invasive potential. Knockout of ITGB8 in this background impairs the cells?? ability to activate latent TGF-??, leading to diminished phosphorylation of SMAD2/3 and reduced expression of downstream mesenchymal markers. This disruption helps uncouple integrin-mediated TGF-?? control from other oncogenic pathways active in A-549 cells, such as EGFR and KRAS signaling. Consequently, the knockout model is especially powerful for exploring how ??v??8-driven TGF-?? activity influences tumor cell plasticity, stromal crosstalk, and fibrotic responses in the lung cancer microenvironment.
Researchers can employ ITGB8 Knockout A-549 Polyclonal Cells for diverse functional readouts, including Western blot analysis of ITGB8 and phospho-SMAD2 levels, RT?qPCR profiling of TGF????responsive genes, and cell adhesion assays on vitronectin or fibronectin substrates. The model further supports TGF??? bioassays and ELISA to quantify cytokine activation, immunofluorescence to assess integrin localization, and Boyden chamber migration/invasion studies. Its polyclonal nature is advantageous for pooled screens, tumor microenvironment reconstructions, and long?term in vitro studies where clonal drift is a concern. Additional applications encompass collagen gel contraction assays to measure contractile force and in vivo tumor xenograft experiments to evaluate the role of ITGB8 in tumor growth and angiogenesis. For further details, please contact Ascent Research.
